You are required to be logged in to access the full website
Click here if you have forgotten your username or password
20 January 2021 - - US-based biotechnology company Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has closed its underwritten public offering of 7,868,421 shares of its common stock at a public offering price of USD 9.50 per share, including 1,026,315 add...
20 January 2021 - - US-based adult stem cell therapies developer BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is highlighting the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy, the c...
20 January 2021 - - German sample and assay technologies provider Qiagen N.V. (NYSE: QGEN) plans to resubmit in 1Q21 its QIAreach SARS-CoV-2 Antigen Test to the US Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 anti...
20 January 2021 - - The US Food and Drug Administration has accepted its supplemental Biologics License Application for Opdivo (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of pat...
20 January 2021 - - The first patient has been dosed in a Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC),...
M2 Pharma brings you breaking news and information on the
global pharmaceuticals industry, helping you to stay one step ahead of the competition.
Click here to subscribe
Click here to subscribe